Cargando…

The Imaging of Insulinomas Using a Radionuclide-Labelled Molecule of the GLP-1 Analogue Liraglutide: A New Application of Liraglutide

OBJECTIVE: This study explores a new, non-invasive imaging method for the specific diagnosis of insulinoma by providing an initial investigation of the use of (125)I-labelled molecules of the glucagon-like peptide-1 (GLP-1) analogue liraglutide for in vivo and in vitro small-animal SPECT/CT (single-...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Jing, Pan, Yu, Li, Xiao, Cheng, Dengfeng, Liu, Shuai, Shi, Hongcheng, Zhang, Yifan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4013070/
https://www.ncbi.nlm.nih.gov/pubmed/24805918
http://dx.doi.org/10.1371/journal.pone.0096833
_version_ 1782315007461031936
author Lv, Jing
Pan, Yu
Li, Xiao
Cheng, Dengfeng
Liu, Shuai
Shi, Hongcheng
Zhang, Yifan
author_facet Lv, Jing
Pan, Yu
Li, Xiao
Cheng, Dengfeng
Liu, Shuai
Shi, Hongcheng
Zhang, Yifan
author_sort Lv, Jing
collection PubMed
description OBJECTIVE: This study explores a new, non-invasive imaging method for the specific diagnosis of insulinoma by providing an initial investigation of the use of (125)I-labelled molecules of the glucagon-like peptide-1 (GLP-1) analogue liraglutide for in vivo and in vitro small-animal SPECT/CT (single-photon emission computed tomography/computed tomography) imaging of insulinomas. METHODS: Liraglutide was labelled with (125)I by the Iodogen method. The labelled (125)I-liraglutide compound and insulinoma cells from the INS-1 cell line were then used for in vitro saturation and competitive binding experiments. In addition, in a nude mouse model, the use of (125)I-liraglutide for the in vivo small-animal SPECT/CT imaging of insulinomas and the resulting distribution of radioactivity across various organs were examined. RESULTS: The labelling of liraglutide with (125)I was successful, yielding a labelling rate of approximately 95% and a radiochemical purity of greater than 95%. For the binding between (125)I-liraglutide and the GLP-1 receptor on the surface of INS-1 cells, the equilibrium dissociation constant (K(d)) was 128.8±30.4 nmol/L(N = 3), and the half-inhibition concentration (IC(50)) was 542.4±187.5 nmol/L(N = 3). Small-animal SPECT/CT imaging with (125)I-liraglutide indicated that the tumour imaging was clearest at 90 min after the (125)I-liraglutide treatment. An examination of the in vivo distribution of radioactivity revealed that at 90 min after the (125)I-liraglutide treatment, the target/non-target (T/NT) ratio for tumour and muscle tissue was 4.83±1.30(N = 3). Our study suggested that (125)I-liraglutide was predominantly metabolised and cleared by the liver and kidneys. CONCLUSION: The radionuclide (125)I-liraglutide can be utilised for the specific imaging of insulinomas, representing a new non-invasive approach for the in vivo diagnosis of insulinomas.
format Online
Article
Text
id pubmed-4013070
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-40130702014-05-09 The Imaging of Insulinomas Using a Radionuclide-Labelled Molecule of the GLP-1 Analogue Liraglutide: A New Application of Liraglutide Lv, Jing Pan, Yu Li, Xiao Cheng, Dengfeng Liu, Shuai Shi, Hongcheng Zhang, Yifan PLoS One Research Article OBJECTIVE: This study explores a new, non-invasive imaging method for the specific diagnosis of insulinoma by providing an initial investigation of the use of (125)I-labelled molecules of the glucagon-like peptide-1 (GLP-1) analogue liraglutide for in vivo and in vitro small-animal SPECT/CT (single-photon emission computed tomography/computed tomography) imaging of insulinomas. METHODS: Liraglutide was labelled with (125)I by the Iodogen method. The labelled (125)I-liraglutide compound and insulinoma cells from the INS-1 cell line were then used for in vitro saturation and competitive binding experiments. In addition, in a nude mouse model, the use of (125)I-liraglutide for the in vivo small-animal SPECT/CT imaging of insulinomas and the resulting distribution of radioactivity across various organs were examined. RESULTS: The labelling of liraglutide with (125)I was successful, yielding a labelling rate of approximately 95% and a radiochemical purity of greater than 95%. For the binding between (125)I-liraglutide and the GLP-1 receptor on the surface of INS-1 cells, the equilibrium dissociation constant (K(d)) was 128.8±30.4 nmol/L(N = 3), and the half-inhibition concentration (IC(50)) was 542.4±187.5 nmol/L(N = 3). Small-animal SPECT/CT imaging with (125)I-liraglutide indicated that the tumour imaging was clearest at 90 min after the (125)I-liraglutide treatment. An examination of the in vivo distribution of radioactivity revealed that at 90 min after the (125)I-liraglutide treatment, the target/non-target (T/NT) ratio for tumour and muscle tissue was 4.83±1.30(N = 3). Our study suggested that (125)I-liraglutide was predominantly metabolised and cleared by the liver and kidneys. CONCLUSION: The radionuclide (125)I-liraglutide can be utilised for the specific imaging of insulinomas, representing a new non-invasive approach for the in vivo diagnosis of insulinomas. Public Library of Science 2014-05-07 /pmc/articles/PMC4013070/ /pubmed/24805918 http://dx.doi.org/10.1371/journal.pone.0096833 Text en © 2014 Lv et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Lv, Jing
Pan, Yu
Li, Xiao
Cheng, Dengfeng
Liu, Shuai
Shi, Hongcheng
Zhang, Yifan
The Imaging of Insulinomas Using a Radionuclide-Labelled Molecule of the GLP-1 Analogue Liraglutide: A New Application of Liraglutide
title The Imaging of Insulinomas Using a Radionuclide-Labelled Molecule of the GLP-1 Analogue Liraglutide: A New Application of Liraglutide
title_full The Imaging of Insulinomas Using a Radionuclide-Labelled Molecule of the GLP-1 Analogue Liraglutide: A New Application of Liraglutide
title_fullStr The Imaging of Insulinomas Using a Radionuclide-Labelled Molecule of the GLP-1 Analogue Liraglutide: A New Application of Liraglutide
title_full_unstemmed The Imaging of Insulinomas Using a Radionuclide-Labelled Molecule of the GLP-1 Analogue Liraglutide: A New Application of Liraglutide
title_short The Imaging of Insulinomas Using a Radionuclide-Labelled Molecule of the GLP-1 Analogue Liraglutide: A New Application of Liraglutide
title_sort imaging of insulinomas using a radionuclide-labelled molecule of the glp-1 analogue liraglutide: a new application of liraglutide
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4013070/
https://www.ncbi.nlm.nih.gov/pubmed/24805918
http://dx.doi.org/10.1371/journal.pone.0096833
work_keys_str_mv AT lvjing theimagingofinsulinomasusingaradionuclidelabelledmoleculeoftheglp1analogueliraglutideanewapplicationofliraglutide
AT panyu theimagingofinsulinomasusingaradionuclidelabelledmoleculeoftheglp1analogueliraglutideanewapplicationofliraglutide
AT lixiao theimagingofinsulinomasusingaradionuclidelabelledmoleculeoftheglp1analogueliraglutideanewapplicationofliraglutide
AT chengdengfeng theimagingofinsulinomasusingaradionuclidelabelledmoleculeoftheglp1analogueliraglutideanewapplicationofliraglutide
AT liushuai theimagingofinsulinomasusingaradionuclidelabelledmoleculeoftheglp1analogueliraglutideanewapplicationofliraglutide
AT shihongcheng theimagingofinsulinomasusingaradionuclidelabelledmoleculeoftheglp1analogueliraglutideanewapplicationofliraglutide
AT zhangyifan theimagingofinsulinomasusingaradionuclidelabelledmoleculeoftheglp1analogueliraglutideanewapplicationofliraglutide
AT lvjing imagingofinsulinomasusingaradionuclidelabelledmoleculeoftheglp1analogueliraglutideanewapplicationofliraglutide
AT panyu imagingofinsulinomasusingaradionuclidelabelledmoleculeoftheglp1analogueliraglutideanewapplicationofliraglutide
AT lixiao imagingofinsulinomasusingaradionuclidelabelledmoleculeoftheglp1analogueliraglutideanewapplicationofliraglutide
AT chengdengfeng imagingofinsulinomasusingaradionuclidelabelledmoleculeoftheglp1analogueliraglutideanewapplicationofliraglutide
AT liushuai imagingofinsulinomasusingaradionuclidelabelledmoleculeoftheglp1analogueliraglutideanewapplicationofliraglutide
AT shihongcheng imagingofinsulinomasusingaradionuclidelabelledmoleculeoftheglp1analogueliraglutideanewapplicationofliraglutide
AT zhangyifan imagingofinsulinomasusingaradionuclidelabelledmoleculeoftheglp1analogueliraglutideanewapplicationofliraglutide